Billionaire Steve Cohen Makes Big Move on Dynavax Technologies Corp (DVAX) Stock

Point72 Asset Management‘s stake in Dynavax Technologies Corp (NASDAQ:DVAX) has been raised according to a recent 13G filing with the Securities and Exchange Commission. Managed by billionaire Steve Cohen, the fund’s holding in the stock stood at 450,346 shares at the end of the second quarter, but has since climbed to 2.28 million shares or 5.9% of Dynavax Technologies’ common stock.

Dynavax Technologies is a clinical-stage biopharmaceutical company. Over the past 12 months, the company’s stock has lost 60.29%. For the second quarter of 2016, Dynavax Technologies reported a net loss of $29 million and a loss per share of $0.75, which compares to a net loss of $23.6 million and a loss per share of $0.80 for the corresponding quarter of 2015.

Hedge fund interest in Dynavax Technologies Corp (NASDAQ:DVAX) plummeted during the second quarter, as the number of long positions held by the funds in our system dropped to 23 as of the end of June, from 29 registered at the end of March. Some of the bullish smart money managers contained Glenn J. Krevlin’s Glenhill Advisors, which held a position valued at $18.79 million, Richard Mashaal’s RIMA Senvest Management, with a position worth $14.55 million, Kevin Kotler’s Broadfin Capital, Scott Scher and Michael Prober’s Clovis Capital Management, and Brian Ashford-Russell and Tim Woolley’s Polar Capital.

Among the investors who lost enthusiasm for investing in Dynavax Technologies Corp (NASDAQ:DVAX) and sold off their positions during the quarter were Richard Driehaus’ Driehaus Capital, which said goodbye to a $2.92 million position, Paul Marshall and Ian Wace’s Marshall Wace LLP, which dumped its position valued at $929,000 at the end of March, Emmanuel Ferreira’s Convector Capital, John Overdeck and David Siegel’s Two Sigma Advisors, and Cliff Asness’ AQR Capital Management.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Page 1 of 11 – SEC Filing